A method of making an antibody in plants that binds to ricin B chain is described. The method comprises (a) introducing a nucleic acid molecule encoding a heavy chain variable region of the antibody and a nucleic acid molecule encoding a light chain variable region of the antibody into a plant or plant cell; and (b) growing the plant or plant cell to obtain a plant that expresses the antibody or antibody fragment. The disclosure also relates to anti-ricin B chain antibodies and antibody fragments as well as methods of using same in therapy and prophylaxis.

A method of making an antibody in plants that binds to ricin B chain is described. The method comprises (a) introducing a nucleic acid molecule encoding a heavy chain variable region of the antibody and a nucleic acid molecule encoding a light chain variable region of the antibody into a plant or plant cell; and (b) growing the plant or plant cell to obtain a plant that expresses the antibody or antibody fragment. The disclosure also relates to anti-ricin B chain antibodies and antibody fragments as well as methods of using same in therapy and prophylaxis.

In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases.

The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases.

A targeted delivery of recombinant therapeutic protein to inhibit the growth of cancer cells is disclosed. The recombinant protein derived from Abrin-a A-chain able to inhibit the growth of cancer cell and conjugated to stxB to form Abrin-f-stxB. The abrin toxin A chain and the Shiga toxin B chain are linked with the furin linker to form a recombinant therapeutic protein as chemotherapeutic agent to inhibit the growth of cancer cells. A conjugate for the delivery of a compound into cancer cells, comprising a first module mediates cell targeting and facilitates cellular uptake, a second module facilitates transport to the endoplasmic reticulum (ER), a third module mediates translocation from the ER to the cytosol and a compound that is desired to be delivered to the cytosol. The recombinant protein Abrin-f-stxB exhibits high binding affinity of stxB as a drug delivery system to Gb3 receptor in targeted cancer diagnosis and treatment.

A targeted delivery of recombinant therapeutic protein to inhibit the growth of cancer cells is disclosed. The recombinant protein derived from Abrin-a A-chain able to inhibit the growth of cancer cell and conjugated to stxB to form Abrin-f-stxB. The abrin toxin A chain and the Shiga toxin B chain are linked with the furin linker to form a recombinant therapeutic protein as chemotherapeutic agent to inhibit the growth of cancer cells. A conjugate for the delivery of a compound into cancer cells, comprising a first module mediates cell targeting and facilitates cellular uptake, a second module facilitates transport to the endoplasmic reticulum (ER), a third module mediates translocation from the ER to the cytosol and a compound that is desired to be delivered to the cytosol. The recombinant protein Abrin-f-stxB exhibits high binding affinity of stxB as a drug delivery system to Gb3 receptor in targeted cancer diagnosis and treatment.

Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.

Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.